Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
906
datasets available to search
ShareScore release 0.9.0
Dataset results
906 results for “atherosclerosis”
Clonal proliferation of smooth muscle cell in human atherosclerosis
GEO Series GSE243179. Homo sapiens. 2 samples. Type: Other.
Role of smooth muscle cell autophagy in atherosclerosis
GEO Series GSE54019. Mus musculus. 4 samples. Type: Expression profiling by array.
Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice
GEO Series GSE210460. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
Data from: Intracranial atherosclerosis on 7T MRI and cognitive functioning – the SMART-MR study
<p><strong>Objective:</strong> To investigate the association between intracranial atherosclerosis (ICAS) and cognitive functioning in patients with a history of vascular disease.</p> <p><strong>Methods:</strong> Within the SMART-MR study cross-sectional analyses were performed in 130 patients (mean±SD age 68±9 years) with 7T vessel wall–magnetic resonance imaging data. Vessel wall lesions were rated according to established criteria and summed into a circulatory and artery-specific ICAS burden. Associations between ICAS burden and Z-scores of memory, executive functioning, working memory and processing speed, were estimated using linear regression analyses adjusted for age, sex, education, reading ability, and vascular risk factors.</p> <p><strong>Results:</strong> A total of 125 patients (96%) had ≥1 vessel wall lesions; the mean ICAS burden was 8.5±5.7.</p> <p>A statistically non-significant association was found between total ICAS burden and memory (b = -0.03 per +1 lesion; 95% CI -0.05 to 0.00). No associations were found for the other domains.</p> <p>A statistically significant association was found for ICAS burden of the posterior cerebral artery (PCA) and memory (b= -0.12 per +1 lesion; 95%CI -0.23 to -0.01) and executive functioning (b= -0.10 per +1 lesion; 95%CI -0.19 to -0.01). Statistically non-significant associations were found for the anterior cerebral artery (ACA) burden and memory (b= -0.13 per +1 lesion; 95%CI -0.26 to 0.01) and executive functioning (b= -0.11 per +1 lesion; 95%CI -0.22 to 0.01).</p> <p>Additional adjustments for large infarcts, white matter hyperintensities, lacunes and ≥50% carotid stenosis, produced similar results.</p> <p><strong>Conclusions:</strong> Our results suggest an artery-specific vulnerability of memory and executive functioning to ICAS, possibly due to strategic brain regions involved with these cognitive domains, which are located in the arterial territory of the PCA and ACA.</p>
Data from: Oral administration of Pantoea agglomerans-derived lipopolysaccharide prevents development of atherosclerosis in high-fat diet-fed apoE-deficient mice via ameliorating hyperlipidemia, pro-inflammatory mediators and oxidative responses
Pantoea agglomerans (P. agglomerans) is a Gram-negative bacterium that grows symbiotically with various edible plants, and the oral or sublingual administration of lipopolysaccharide derived from P. agglomerans (LPSp) have been suggested to contribute to prevention of immune-related diseases. Our previous study indicated that orally administered LPSp was shown to exhibit an LDL-lowering effect in hyperlipidemic volunteers; however, a preventive effect of LPSp on atherosclerosis is unclear. The present study attempted to evaluate the anti-atherosclerotic effect by LPSp in a mouse model of high-fat diet (HFD)-induced atherosclerosis. For 16 weeks, apoE-deficient mice were fed an HFD and received drinking water containing LPSp (0.3 or 1 mg/kg body weight/day). The results showed that the orally administered LPSp decreased body weight. A significant reduction in atherosclerotic plaque deposition was observed even with the lower dose of LPSp. The biochemical analyses showed that LPSp markedly improved glucose tolerance and reduced plasma LDL and oxidized LDL levels. In addition, LPSp significantly reduced the production of pro-inflammatory mediators including MCP-1 (in the plasma), TNF-α and IL-6 (in the colon), and decreased the oxidative burst activities in the peripheral blood sample. Taken together, these results suggest the possibility that oral administration of LPSp can effectively ameliorate HFD-induced hyperlipidemia and inflammatory/oxidative responses to prevent atherosclerosis and related metabolic disorders.
Multiomics analysis of concurrent MASH and atherosclerosis in male and female mice
<p><span>Metabolic dysfunction-associated steatohepatitis (MASH) has reached epidemic proportions with limited therapies available. Surprisingly, the leading cause of death in these patients is atherosclerotic cardiovascular disease. No pharmacological therapy exists to treat MASH and atherosclerosis simultaneously, which is attributed to the lack of translational mouse models, particularly in females. Herein, we have utilized both male and female atheroprone mice, combined with different high-fat diets containing physiologically relevant cholesterol levels, to model concurrent MASH-atherosclerosis. Upon phenotypic characterization using standard histopathology, immunohistochemistry, and biochemical assays on liver, cardiovascular, and plasma samples, we report the first female MASH-atherosclerosis model. Furthermore, we conducted a multi-omics exploration of metabolomic, lipidomic, and transcriptomic profiles altered within these groups, and found metabolic and genomic signatures comparable to the human disease. These models will facilitate future cardiometabolic research to unravel the molecular and metabolic underpinnings at the intersection of MASH and atherosclerosis, which must be pharmacologically targeted.</span></p>
Epidemiology of Plasma Fatty Acids and Atherosclerosis
ClinicalTrials.gov study NCT00005226. IPD Sharing: Not stated. Countries: 0. Publications: 4.
PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
ClinicalTrials.gov study NCT04176978. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
ClinicalTrials.gov study NCT05476991. IPD Sharing: NO. Countries: 1. Publications: 0.
A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients
ClinicalTrials.gov study NCT07111442. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Detection of Subclinical Atherosclerosis in Asymptomatic Individuals
ClinicalTrials.gov study NCT00862056. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
ClinicalTrials.gov study NCT05708859. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules
ClinicalTrials.gov study NCT06166121. IPD Sharing: NO. Countries: 1. Publications: 0.
Visualization of Carotid Atherosclerosis by 68Ga-MSA
ClinicalTrials.gov study NCT01893489. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Pat
ClinicalTrials.gov study NCT00516880. IPD Sharing: Not stated. Countries: 1. Publications: 0.
High-risk Coronary Atherosclerosis in Subjects With Family History of Myocardial Infarction
ClinicalTrials.gov study NCT07352111. IPD Sharing: NO. Countries: 1. Publications: 0.
Fat Induced Insulin Resistance and Atherosclerosis
ClinicalTrials.gov study NCT02348190. IPD Sharing: Not stated. Countries: 1. Publications: 0.
DETECTion of the Prevalence of Silent Atherosclerosis Across Adult Life
ClinicalTrials.gov study NCT06692127. IPD Sharing: NO. Countries: 2. Publications: 0.
Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT
ClinicalTrials.gov study NCT01589224. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors
ClinicalTrials.gov study NCT00666250. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.